Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET
Alzheimer's & Dementia · 2025-02 · 21 (2)
DOI: 10.1002/alz.14571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 12.02.2025. Verfasst von Elijah Mak und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, alpha-Synuclein, Glucose, Brain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIH HHS, Liston Award.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION We investigated the association between alpha‐synuclein (α‐syn) pathology and brain glucose metabolism across the cognitive spectrum of Alzheimer's disease (AD) co‐pathologies. METHODS Fluorodeoxyglucose positron emission tomography (FDG‐PET) data from 829 Alzheimer's Disease Neuroimaging Initiative participants (648 cognitively impaired [CI], 181 unimpaired [CU]) were compared between α‐syn seed amplification assay (SAA) positive and negative groups. Interactions with cerebrospinal fluid (CSF) AD biomarkers were examined. RESULTS SAA+ was associated with widespread hypometabolism among CI individuals, particularly in posterior cortical regions, independent of CSF amyloid and tau levels in the occipital lobes. Regional hypometabolism mediated the effect of α‐syn SAA on disease severity in CI individuals, independent of CSF amyloid and tau levels. There were no influences of SAA on FDG‐PET in CU individuals. DISCUSSION This study supports a model in which α‐syn aggregation influences metabolic dysfunction, which then influences clinical disease severity, independent of AD. SAA+ could help optimize participant selection and outcome measures for clinical trials in AD. Highlights α‐synuclein seed amplification positivity (SAA+) was associated with hypometabolism in cognitively impaired individuals. Hypometabolism mediated the influence of α‐synuclein on disease severity. Occipital hypometabolism in SAA+ was independent of cerebrospinal fluid levels of Alzheimer's disease pathology. These findings can optimize future clinical trials targeting α‐synuclein pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Psychiatry, University of Cambridge School of Clinical Medicine, Cambridge, UK.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Information Technology, Mayo Clinic, Rochester, Minnesota, USA.
- Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Förderung
- NIA NIH HHS
- NIH HHS
- Liston Award
- Schuler Foundation
- Little Family Foundation
- NINDS NIH HHS
- Elsie and Marvin Dekelboum Family Foundation
- NCRR NIH HHS
Zitieren
APA
Mak, E., Przybelski, S. A., Wiste, H. J., Fought, A. J., Schwarz, C. G., Senjem, M. L., Jack, C. R., Lowe, V. J., Petersen, R. C., Boeve, B. F., O'Brien, J. T., Kantarci, K., & Alzheimer's Disease Neuroimaging Initiative (2025). Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET. Alzheimer's & Dementia, 21(2). https://doi.org/10.1002/alz.14571
Vancouver
Mak E, Przybelski SA, Wiste HJ, Fought AJ, Schwarz CG, Senjem ML, et al. Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET. Alzheimer's & Dementia. 2025;21(2). doi:10.1002/alz.14571
BibTeX
@article{Mak2025,
author = {Mak, Elijah and Przybelski, Scott A and Wiste, Heather J and Fought, Angela J and Schwarz, Christopher G and Senjem, Matthew L and Jack, Clifford R and Lowe, Val J and Petersen, Ronald C and Boeve, Bradley F and O'Brien, John T and Kantarci, Kejal and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
title = {Influence of alpha‐synuclein on glucose metabolism in Alzheimer's disease continuum: Analyses of α‐synuclein seed amplification assay and FDG‐PET},
journal = {Alzheimer's & Dementia},
year = {2025},
volume = {21},
number = {2},
doi = {10.1002/alz.14571}
}
EUVIMED